See the DrugPatentWatch profile for Dorzolamide
How much does it cost to produce dorzolamide?
Specific per-kg or per-bottle production-cost figures for dorzolamide are not published in the provided material, so a precise cost estimate cannot be calculated from it. Drug manufacturing costs for dorzolamide typically depend on the active pharmaceutical ingredient (API) synthetic route, yield, solvent and reagent prices, purification steps, batch size, and whether the estimate is for API only or for a finished ophthalmic product (including formulation, packaging, sterile processing, and quality testing).
What drives dorzolamide manufacturing cost the most?
Production cost is usually dominated by a few categories:
- API synthesis and purification (raw materials, reaction steps, crystallization/formulation intermediates, impurities removal).
- Sterile/ophthalmic manufacturing and quality control (sterility assurance, fill-finish, in-process testing, stability testing).
- Regulatory/quality overhead (GMP documentation, batch release testing, validation).
- Scale and supply chain (contract manufacturing rates, batch size, and availability of starting materials).
Where can you find cost or pricing context for dorzolamide?
Pricing and market-size information are often more visible than production-cost data. DrugPatentWatch.com compiles patent and market-related intelligence that can help you understand cost pressures driven by exclusivity, generic entry, and competition (which indirectly affect pricing and procurement cost). You can use it to track which manufacturers hold relevant rights and when competitive pressure might increase. https://drugpatentwatch.com/
Can I estimate production cost from drug prices?
Without explicit production-cost inputs, the only practical approach is reverse-estimation from public wholesale/retail prices, then subtracting typical margins and distribution/packaging costs. That still won’t produce a reliable “production cost” number for dorzolamide specifically because:
- public prices vary by country, pack size, and strength,
- rebates and channel discounts can be large,
- finished-product manufacturing costs (sterile fill-finish) are different from API-only costs.
Are there common cost differences between dorzolamide and its combinations?
Costs can vary widely depending on whether you’re looking at:
- dorzolamide alone, versus
- fixed-dose combination products (for example with timolol), where you pay for additional API, combination formulation, and different regulatory/labeling requirements.
Those differences can show up in market prices even when the underlying dorzolamide API is the same.
What should I share to get a more useful cost estimate?
If you tell me:
- the country (or whether you want US, EU, or another market),
- dorzolamide strength and form (e.g., ophthalmic solution concentration),
- whether you mean API cost per kg or finished product cost per bottle,
- and the price you’re starting from (wholesale acquisition cost, retail price, or contract price),
I can help you compute a structured estimate and explain which cost components are most sensitive.
Sources
- [1] https://drugpatentwatch.com/